AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Patients remaining on alglucosidase alfa + pbo demonstrated statistically significant worsening for several lung function outcomes, biomarker levels, and significant improvement for PROMIS-Dyspnea. Additional details of the analysis methodology can be found below. “Across the different domains in this analysis, patients who switched to Pombiliti + Opfolda experienced stability or improvement on many measures, including 6-minute walking distance and PROMIS-Fatigue, compared to those who remained on alglucosidase alfa who primarily stayed stable or experienced worsening,” said Hani A. Kushlaf, MD, Professor of Neurology and Pathology, University of Cincinnati. “Given that LOPD is a progressive condition, it’s imperative that physicians assess when patients should consider switching to Pombiliti + Opfolda.” “The consistency of stability or improvement across multiple domains in the cohort of ERT-experienced patients from PROPEL – including measures of biomarkers, muscle strength, motor function, pulmonary function, and quality of life – is highly encouraging in a disease known for its relentless progression,” said Jeff Castelli, PhD, Chief Development Officer, Amicus Therapeutics, Inc.
“We view these results as further validation of the differentiated mechanism and clinical profile of Pombiliti + Opfolda and remain committed to advancing therapies that make a tangible difference in the lives of people living with late-onset Pompe disease.” About the PROPEL Study PROPEL was a 52-week, double-blind randomized global study designed to assess the efficacy, safety, and tolerability of cipaglucosidase alfa-atga + miglustat compared to non-U.S. approved alglucosidase alfa + placebo (the comparator). The study enrolled 123 adult LOPD patients who still had the ability to walk and to breathe without mechanical ventilation. Patients enrolled in PROPEL were randomized 2:1 so that for every two patients randomized to be treated with cipaglucosidase alfa-atga + miglustat, one was randomized to be treated with the comparator. Of the patients enrolled in PROPEL, 77% were being treated with alglucosidase alfa (n=95) for at least 2 years at study entry and 23% had never been treated with any ERT (n=28).
117 of the 123 patients (>95%) completed the PROPEL study. Efficacy endpoints of the study included primary endpoint of change from baseline to week 52 in 6-minute walk distance (6MWD) for comparison of superiority and key secondary endpoint of change from baseline to week 52 in forced vital capacity (FVC). PROPEL did not achieve statistical significance for the primary endpoint of superiority in change from baseline to week 52 in 6MWD in the overall population. After 52 weeks, ERT-experienced patients treated with cipaglucosidase alfa-atga + miglustat (n=61) walked an estimated 17 meters (95% CI, 0.2, 33) farther than the comparator group (n=29). After 52 weeks, ERT-experienced patients treated with cipaglucosidase alfa-atga + miglustat (n=55) showed an estimated treatment difference of 3.5% (95% CI, 1.0, 6.0) in FVC compared with the comparator group (n=29).
More details about this post-hoc analysis This post-hoc analysis assessed the magnitude of within-group treatment effects across measures of motor function, muscle strength, pulmonary function, patient-reported outcomes/QoL measures, and biomarkers. Standardized effect size analysis describes the absolute effect size relative to the variability of the data. It transforms the effect size into a scale with no units of measurement (Cohen’s d). The authors calculated standardized within-group effect sizes (Cohen’s d for within-group comparisons) and corresponding 95% CIs for the change from baseline to week 52 for the primary, secondary, and pharmacodynamic endpoints of the PROPEL study. Standardized within-group effect sizes and corresponding 95% CIs were calculated by dividing the mean change from baseline values and CIs at week 52 by the standard deviation (SD) of the difference scores.
Consistent with medical literature, effect sizes were defined as stable (−0.2 < d < 0.2), small (0.2 ≤ d < 0.5), medium (0.5 ≤ d < 0.8), or large (d ≥ 0.8) improvement, or as small (−0.5 < d ≤ −0.2), medium (−0.8 < d ≤ −0.5), or large (d ≤ −0.8) worsening, and were considered statistically significant if the standardized 95% CIs did not cross zero. About Pombiliti + Opfolda Pombiliti® + Opfolda®, is a two-component therapy that consists of cipaglucosidase alfa-atga, a bis-M6P-enriched rhGAA that facilitates high-affinity uptake through the M6P receptor while retaining its capacity for processing into the most active form of the enzyme, and the oral enzyme stabilizer, miglustat, that’s designed to reduce loss of enzyme activity in the blood. U.S. INDICATIONS AND USAGE POMBILITI in combination with OPFOLDA is indicated for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT). SAFETY INFORMATION HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS: Appropriate medical support measures, including cardiopulmonary resuscitation equipment, should be readily available.
If a severe hypersensitivity reaction occurs, POMBILITI should be discontinued immediately and appropriate medical treatment should be initiated. INFUSION-ASSOCIATED REACTIONS (IARs): If severe IARs occur, immediately discontinue POMBILITI and initiate appropriate medical treatment. RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS: Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function, may be at risk of serious exacerbation of their cardiac or respiratory status during POMBILITI infusion. See PI for complete Boxed Warning. CONTRAINDICATION: POMBILITI in combination with Opfolda is contraindicated in pregnancy.
EMBRYO-FETAL TOXICITY: May cause embryo-fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for at least 60 days after the last dose. Adverse Reactions: Most common adverse reactions ≥ 5% are headache, diarrhea, fatigue, nausea, abdominal pain, and pyrexia. Please see full PRESCRIBING INFORMATION, including BOXED WARNING, for POMBILITI (cipaglucosidase alfa-atga) LINK and full PRESCRIBING INFORMATION for OPFOLDA (miglustat) LINK. About Late-Onset Pompe Disease Late-onset Pompe disease is an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA).
Reduced or absent levels of GAA lead to accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. Late-onset Pompe disease can be severe and debilitating with progressive muscle weakness throughout the body that worsens over time, particularly skeletal muscles and muscles that control breathing. About Amicus Therapeutics Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
PP-AT-ALL-0001-0525 CONTACTS: Investors: Amicus Therapeutics Andrew Faughnan Vice President, Investor Relations [email protected] (609) 662-3809 Media: Amicus Therapeutics Diana Moore Vice President, Corporate Communications [email protected] (609) 662-5079 FOLD–G
